Thomas Steyer’s Regenxbio RGNX Stock Holding History

Thomas Steyer’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-417,000	Closed	-$13.7M	–	87
2017 Q3	$13.7M	Buy	+417,000	New	+$9.38M	0.12%	65

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Thomas Steyer's RGNX Position: Q4 2017 in Review

Thomas Steyer sold out of Regenxbio (RGNX) in Q4 2017, closing a stake of 417,000 shares — an estimated $13.7M sold.

Thomas Steyer first reported a position in RGNX in Q3 2017 and held it in 1 quarter. The position peaked at $13.7M in Q3 2017. 108 funds tracked by Wall St. Rank hold RGNX as of Q4 2017.

Thomas Steyer reported no remaining Regenxbio position as of Q4 2017 after selling out during the quarter.
Thomas Steyer sold 417,000 Regenxbio shares in Q4 2017, an estimated $13.7M.
Thomas Steyer first reported a position in Regenxbio in Q3 2017 and held it in 1 quarter.
Thomas Steyer's Regenxbio position peaked at $13.7M in Q3 2017.
108 funds tracked by Wall St. Rank held Regenxbio as of Q4 2017.

Based on Farallon Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.